The findings will allow for more targeted treatment approaches.
In a new study, the OMRF compound OKN-007 is being combined with the current standard-of-care medication for glioblastoma.
The findings will help push clinicians closer to personalized medicine for lupus sufferers.
OMRF scientists Tim Griffin and Albert Batushansky are pushing the bounds of a decades-old scientific method to study the origins of osteoarthritis.
New research from OMRF is taking physicians closer to personalized treatment solutions for patients suffering from lupus.
Arthritis is the leading cause of disability in adults in the U.S. Understandably, this has led to much concern about the future of arthritis treatment.